{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:40Z","timestamp":1786982380406,"version":"build-2736575974"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03348-8","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:13:12Z","timestamp":1758615192000},"page":"5742-5760","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Number Needed to Treat and Cost Per Responder Analysis of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in Adults for Whom Prior Preventive Treatments have Failed"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4691-3388","authenticated-orcid":false,"given":"Dimos D.","family":"Mitsikostas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5060-7404","authenticated-orcid":false,"given":"Susanne F.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"Kongerslev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3062-8881","authenticated-orcid":false,"given":"Line Pickering","family":"Boserup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1102-3756","authenticated-orcid":false,"given":"Xin Ying","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinder","family":"Phul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0651-1939","authenticated-orcid":false,"given":"Simona","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"issue":"10283","key":"3348_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Ozge A, et al. Migraine: epidemiology and systems of care. Lancet. 2021;397(10283):1485\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(20)32160-7.","journal-title":"Lancet"},{"issue":"8","key":"3348_CR2","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/head.13613","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Fanning KM, Reed ML, Murray S, Dumas PK, Adams AM, et al. Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache. 2019;59(8):1286\u201399. https:\/\/doi.org\/10.1111\/head.13613.","journal-title":"Headache"},{"issue":"5","key":"3348_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343\u20139. https:\/\/doi.org\/10.1212\/01.wnl.0000252808.97649.21.","journal-title":"Neurology"},{"issue":"Suppl 1","key":"3348_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/head.13301","volume":"58","author":"R Agosti","year":"2018","unstructured":"Agosti R. Migraine burden of disease: from the patient\u2019s experience to a socio-economic view. Headache. 2018;58(Suppl 1):17\u201332. https:\/\/doi.org\/10.1111\/head.13301.","journal-title":"Headache"},{"issue":"5","key":"3348_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10194-012-0460-7","volume":"13","author":"LM Bloudek","year":"2012","unstructured":"Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13(5):361\u201378. https:\/\/doi.org\/10.1007\/s10194-012-0460-7.","journal-title":"J Headache Pain"},{"issue":"5","key":"3348_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"M Linde","year":"2012","unstructured":"Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barre J, Katsarava Z, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19(5):703\u201311. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03612.x.","journal-title":"Eur J Neurol"},{"issue":"1","key":"3348_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-023-01652-8","volume":"24","author":"G Vaghi","year":"2023","unstructured":"Vaghi G, De Icco R, Tassorelli C, Goadsby PJ, Vicente-Herrero T, de la Torre ER. Who cares about migraine? Pathways and hurdles in the European region\u2014access to care III. J Headache Pain. 2023;24(1):120. https:\/\/doi.org\/10.1186\/s10194-023-01652-8.","journal-title":"J Headache Pain"},{"issue":"7","key":"3348_CR8","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021\u201339. https:\/\/doi.org\/10.1111\/head.14153.","journal-title":"Headache"},{"issue":"1","key":"3348_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update. J Headache Pain. 2022;23(1):67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x.","journal-title":"J Headache Pain"},{"issue":"2","key":"3348_CR10","doi-asserted-by":"publisher","first-page":"333102425132060","DOI":"10.1177\/03331024251320608","volume":"45","author":"S Sacco","year":"2025","unstructured":"Sacco S, Ashina M, Diener HC, Haghdoost F, Lee MJ, Monteith TS, et al. Setting higher standards for migraine prevention: a position statement of the International Headache Society. Cephalalgia. 2025;45(2):3331024251320608. https:\/\/doi.org\/10.1177\/03331024251320608.","journal-title":"Cephalalgia"},{"issue":"4","key":"3348_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/03331024231159366","volume":"43","author":"F Haghdoost","year":"2023","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023;43(4):1\u201314. https:\/\/doi.org\/10.1177\/03331024231159366.","journal-title":"Cephalalgia"},{"issue":"8","key":"3348_CR12","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1007\/s12325-021-01848-x","volume":"38","author":"L Citrome","year":"2021","unstructured":"Citrome L, Sanchez Del Rio M, Dong Y, Nichols RM, Tockhorn-Heidenreich A, Foster SA, et al. Benefit-risk assessment of galcanezumab versus placebo for the treatment of episodic and chronic migraine using the metrics of number needed to treat and number needed to harm. Adv Ther. 2021;38(8):4442\u201360. https:\/\/doi.org\/10.1007\/s12325-021-01848-x.","journal-title":"Adv Ther"},{"issue":"3","key":"3348_CR13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jclinepi.2005.08.005","volume":"59","author":"CA Chong","year":"2006","unstructured":"Chong CA, Tomlinson G, Chodirker L, Figdor N, Uster M, Naglie G, et al. An unadjusted NNT was a moderately good predictor of health benefit. J Clin Epidemiol. 2006;59(3):224\u201333. https:\/\/doi.org\/10.1016\/j.jclinepi.2005.08.005.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"3348_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Headache. 2024;64(4):333\u201341. https:\/\/doi.org\/10.1111\/head.14692.","journal-title":"Headache"},{"issue":"1","key":"3348_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s10194-024-01727-0","volume":"25","author":"C Lazaro-Hernandez","year":"2024","unstructured":"Lazaro-Hernandez C, Caronna E, Rosell-Mirmi J, Gallardo VJ, Alpuente A, Torres-Ferrus M, et al. Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population. J Headache Pain. 2024;25(1):21. https:\/\/doi.org\/10.1186\/s10194-024-01727-0.","journal-title":"J Headache Pain"},{"issue":"1","key":"3348_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s10194-023-01682-2","volume":"24","author":"JB Hong","year":"2023","unstructured":"Hong JB, Lange KS, Fitzek M, Overeem LH, Triller P, Siebert A, et al. Impact of a reimbursement policy change on treatment with erenumab in migraine\u2014a real-world experience from Germany. J Headache Pain. 2023;24(1):144. https:\/\/doi.org\/10.1186\/s10194-023-01682-2.","journal-title":"J Headache Pain"},{"issue":"1","key":"3348_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s10194-022-01476-y","volume":"23","author":"JL Nguyen","year":"2022","unstructured":"Nguyen JL, Munshi K, Peasah SK, Swart ECS, Kohli M, Henderson R, et al. Trends in utilization and costs of migraine medications, 2017\u20132020. J Headache Pain. 2022;23(1):111. https:\/\/doi.org\/10.1186\/s10194-022-01476-y.","journal-title":"J Headache Pain"},{"key":"3348_CR18","unstructured":"AIMOVIG\u00ae (erenumab-aooe) injection, for subcutaneous use. Prescribing information. Amgen Inc.; 2025. Accessed August 5, 2025. Available from: https:\/\/www.aimovig.com\/."},{"key":"3348_CR19","unstructured":"EMGALITY\u00ae (galcanezumab-gnlm) injection, for subcutaneous use. Prescribing information. Eli Lilly and Company; 2025. Accessed August 5, 2025. Available from: https:\/\/emgality.lilly.com\/."},{"key":"3348_CR20","unstructured":"AJOVY\u00ae (fremanezumab-vfrm) injection, for subcutaneous use. Prescribing information. Teva Pharmaceuticals USA, Inc.; 2025. Accessed August 5, 2025. Available from: https:\/\/www.ajovy.com\/."},{"key":"3348_CR21","unstructured":"VYEPTI\u00ae (eptinezumab-jjmr) injection, for intravenous use. Prescribing information. Lundbeck Seattle BioPharmaceuticals, Inc.; 2025. Accessed August 5, 2025. Available from: https:\/\/www.vyepti.com\/."},{"key":"3348_CR22","unstructured":"European Medicines Agency (EMA). Aimovig: EPAR - Medicine Overview. 2019. Accessed July 30, 2025. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/aimovig."},{"key":"3348_CR23","unstructured":"European Medicines Agency (EMA). Emgality: EPAR - Medicine Overview. 2019. Accessed July 30, 2025. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/emgality."},{"key":"3348_CR24","unstructured":"European Medicines Agency (EMA). Ajovy: EPAR - Medicine Overview. 2019. Accessed July 30, 2025. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ajovy."},{"key":"3348_CR25","unstructured":"European Medicines Agency (EMA). Vyepti: EPAR - Medicine Overview. 2022. Accessed July 30, 2025. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vyepti."},{"issue":"1","key":"3348_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000547","volume":"6","author":"JC Ray","year":"2024","unstructured":"Ray JC, Dalic L, Baker J, Cheng S, Hutton EJ, Matharu M. Twelve-month efficacy of CGRP monoclonal antibodies and predictive value of short-term response: results of an Australian multicentre study. BMJ Neurol Open. 2024;6(1): e000547. https:\/\/doi.org\/10.1136\/bmjno-2023-000547.","journal-title":"BMJ Neurol Open"},{"issue":"1","key":"3348_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, MaassenVanDenBrink A, Deligianni CI, Gil-Gouveia R, Jassal T, Sanchez-Del-Rio M, et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain. 2023;24(1):56. https:\/\/doi.org\/10.1186\/s10194-023-01594-1.","journal-title":"J Headache Pain"},{"issue":"8","key":"3348_CR28","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.jval.2024.04.002","volume":"27","author":"A Smith","year":"2024","unstructured":"Smith A, Finnigan K, Clarke S, Barry M, Gorry C. Utilization, expenditure, and treatment patterns associated with calcitonin gene-related peptide monoclonal antibodies reimbursed subject to a managed access protocol in Ireland. Value Health. 2024;27(8):1039\u201345. https:\/\/doi.org\/10.1016\/j.jval.2024.04.002.","journal-title":"Value Health"},{"key":"3348_CR29","doi-asserted-by":"publisher","unstructured":"Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs. other preventive migraine treatments in the United States. J Manag Care Spec Pharm 2022;28(8):818\u201329. https:\/\/doi.org\/10.18553\/jmcp.2022.28.8.818","DOI":"10.18553\/jmcp.2022.28.8.818"},{"issue":"10","key":"3348_CR30","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40261-019-00827-z","volume":"39","author":"TV Giannouchos","year":"2019","unstructured":"Giannouchos TV, Mitsikostas DD, Ohsfeldt RL, Vozikis A, Koufopoulou P. Cost-effectiveness analysis of erenumab versus onabotulinumtoxina for patients with chronic migraine attacks in Greece. Clin Drug Investig. 2019;39(10):979\u201390. https:\/\/doi.org\/10.1007\/s40261-019-00827-z.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"3348_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s10194-024-01749-8","volume":"25","author":"E Griffin","year":"2024","unstructured":"Griffin E, Shirley G, Lee XY, Awad SF, Tyagi A, Goadsby PJ. An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity. J Headache Pain. 2024;25(1):59. https:\/\/doi.org\/10.1186\/s10194-024-01749-8.","journal-title":"J Headache Pain"},{"issue":"1","key":"3348_CR32","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s10194-022-01492-y","volume":"23","author":"S Khanal","year":"2022","unstructured":"Khanal S, Underwood M, Naghdi S, Brown A, Duncan C, Matharu M, et al. A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine. J Headache Pain. 2022;23(1):122. https:\/\/doi.org\/10.1186\/s10194-022-01492-y.","journal-title":"J Headache Pain"},{"issue":"8","key":"3348_CR33","doi-asserted-by":"publisher","first-page":"E607","DOI":"10.1001\/amajethics.2021.607","volume":"23","author":"HS Smith","year":"2021","unstructured":"Smith HS. How should economic value be considered in treatment decisions for individual patients? AMA J Ethics. 2021;23(8):E607\u201312. https:\/\/doi.org\/10.1001\/amajethics.2021.607.","journal-title":"AMA J Ethics"},{"issue":"1","key":"3348_CR34","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12916-017-0875-8","volume":"15","author":"D Mendes","year":"2017","unstructured":"Mendes D, Alves C, Batel-Marques F. Number needed to treat (NNT) in clinical literature: an appraisal. BMC Med. 2017;15(1):112. https:\/\/doi.org\/10.1186\/s12916-017-0875-8.","journal-title":"BMC Med"},{"issue":"5","key":"3348_CR35","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/03007995.2021.2003127","volume":"38","author":"SA Foster","year":"2022","unstructured":"Foster SA, Hoyt M, Ye W, Mason O, Ford JH. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes. Curr Med Res Opin. 2022;38(5):653\u201360. https:\/\/doi.org\/10.1080\/03007995.2021.2003127.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"3348_CR36","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"21","author":"M Ashina","year":"2022","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK, et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21(7):597\u2013607. https:\/\/doi.org\/10.1016\/S1474-4422(22)00185-5.","journal-title":"Lancet Neurol"},{"issue":"10203","key":"3348_CR37","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"M Ferrari","year":"2019","unstructured":"Ferrari M, Diener H, Ning X, Galic M, Cohen J, Yang R, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394(10203):1030\u201340.","journal-title":"Lancet"},{"issue":"10","key":"3348_CR38","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, Lainez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19(10):814\u201325. https:\/\/doi.org\/10.1016\/S1474-4422(20)30279-9.","journal-title":"Lancet Neurol"},{"issue":"10161","key":"3348_CR39","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(18)32534-0.","journal-title":"Lancet"},{"key":"3348_CR40","unstructured":"National Institute for Health and Care Excellence (NICE). Technology appraisal guidance: Fremanezumab for preventing migraine [TA764]. 2022. Accessed July 24, 2025. Available from: https:\/\/www.nice.org.uk\/guidance\/ta764."},{"key":"3348_CR41","unstructured":"National Institute for Health and Care Excellence (NICE). Technology appraisal guidance: Galcanezumab for preventing migraine [TA659]. 2020. Accessed July 24, 2025. Available from: https:\/\/www.nice.org.uk\/guidance\/ta659."},{"key":"3348_CR42","unstructured":"National Institute for Health and Care Excellence (NICE). Technology appraisal guidance: Eptinezumab for preventing migraine [TA871]. 2023. Accessed July 24, 2025. Available from: https:\/\/www.nice.org.uk\/guidance\/TA871."},{"key":"3348_CR43","unstructured":"National Institute for Health and Care Excellence (NICE). Technology appraisal guidance: Erenumab for preventing migraine [TA682]. 2021. Accessed July 24, 2025. Available from: https:\/\/www.nice.org.uk\/guidance\/ta682."},{"issue":"1","key":"3348_CR44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s10194-022-01472-2","volume":"23","author":"X Wang","year":"2022","unstructured":"Wang X, Wen D, He Q, You C, Ma L. Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis. J Headache Pain. 2022;23(1):105. https:\/\/doi.org\/10.1186\/s10194-022-01472-2.","journal-title":"J Headache Pain"},{"issue":"6","key":"3348_CR45","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1177\/1591019919858733","volume":"25","author":"JC Martinez-Gutierrez","year":"2019","unstructured":"Martinez-Gutierrez JC, Leslie-Mazwi T, Chandra RV, Ong KL, Nogueira RG, Goyal M, et al. Number needed to treat: a primer for neurointerventionalists. Interv Neuroradiol. 2019;25(6):613\u20138. https:\/\/doi.org\/10.1177\/1591019919858733.","journal-title":"Interv Neuroradiol"},{"issue":"4","key":"3348_CR46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/ebmental-2020-300232","volume":"24","author":"V Vancak","year":"2021","unstructured":"Vancak V, Goldberg Y, Levine SZ. Guidelines to understand and compute the number needed to treat. Evid Based Ment Health. 2021;24(4):131\u20136. https:\/\/doi.org\/10.1136\/ebmental-2020-300232.","journal-title":"Evid Based Ment Health"},{"issue":"26","key":"3348_CR47","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","volume":"318","author":"A Laupacis","year":"1988","unstructured":"Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318(26):1728\u201333. https:\/\/doi.org\/10.1056\/NEJM198806303182605.","journal-title":"N Engl J Med"},{"key":"3348_CR48","unstructured":"Richard T, Vanhaeverbeek M, Van Meerhaeghe A. [The number needed to treat (NNT)]. Rev Med Brux. 2011;32(5):453\u20138. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22165523"},{"issue":"10","key":"3348_CR49","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/head.14824","volume":"64","author":"J Ailani","year":"2024","unstructured":"Ailani J, Gandhi P, Lalla A, Halker Singh R, McAllister P, Smith JH, et al. Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine. Headache. 2024;64(10):1253\u201363. https:\/\/doi.org\/10.1111\/head.14824.","journal-title":"Headache"},{"issue":"5","key":"3348_CR50","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ijcp.12142","volume":"67","author":"L Citrome","year":"2013","unstructured":"Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407\u201311. https:\/\/doi.org\/10.1111\/ijcp.12142.","journal-title":"Int J Clin Pract"},{"issue":"7","key":"3348_CR51","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1177\/0333102421989601","volume":"41","author":"K Drellia","year":"2021","unstructured":"Drellia K, Kokoti L, Deligianni CI, Papadopoulos D, Mitsikostas DD. Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. Cephalalgia. 2021;41(7):851\u201364. https:\/\/doi.org\/10.1177\/0333102421989601.","journal-title":"Cephalalgia"},{"issue":"7","key":"3348_CR52","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/17581869.2025.2509474","volume":"15","author":"SI Christofilos","year":"2025","unstructured":"Christofilos SI, Mavridis T, Gkotzamanis V, Vasilopoulou S, Deligianni CI, Dimos-Dimitrios M. Repurposed versus disease-specific medicinals for the prophylaxis of migraine: an updated systematic review. Pain Manag. 2025;15(7):425\u201339. https:\/\/doi.org\/10.1080\/17581869.2025.2509474.","journal-title":"Pain Manag"},{"issue":"6","key":"3348_CR53","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.62458","volume":"16","author":"M Kodounis","year":"2024","unstructured":"Kodounis M, Constantinidis TS, Rizonaki K, Drakou E, Zintzaras E, Stefanidis I, et al. A risk-difference meta-analysis for the prophylactic treatments of chronic migraine. Cureus. 2024;16(6): e62458. https:\/\/doi.org\/10.7759\/cureus.62458.","journal-title":"Cureus"},{"issue":"3","key":"3348_CR54","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241\u201354. https:\/\/doi.org\/10.1177\/0333102420905132.","journal-title":"Cephalalgia"},{"issue":"10","key":"3348_CR55","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.neurol.2020.04.027","volume":"176","author":"J Schoenen","year":"2020","unstructured":"Schoenen J, Manise M, Nonis R, Gerard P, Timmermans G. Monoclonal antibodies blocking CGRP transmission: an update on their added value in migraine prevention. Rev Neurol (Paris). 2020;176(10):788\u2013803. https:\/\/doi.org\/10.1016\/j.neurol.2020.04.027.","journal-title":"Rev Neurol (Paris)"},{"issue":"13","key":"3348_CR56","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365\u201377. https:\/\/doi.org\/10.1212\/WNL.0000000000009169.","journal-title":"Neurology"},{"issue":"6","key":"3348_CR57","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1177\/0018578718797295","volume":"53","author":"K Stoker","year":"2018","unstructured":"Stoker K, Baker DE. Erenumab-aooe. Hosp Pharm. 2018;53(6):363\u20138. https:\/\/doi.org\/10.1177\/0018578718797295.","journal-title":"Hosp Pharm"},{"key":"3348_CR58","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2147\/CEOR.S180491","volume":"10","author":"JP Jansen","year":"2018","unstructured":"Jansen JP, Khalid JM, Smyth MD, Patel H. The number needed to treat and relevant between-trial comparisons of competing interventions. Clinicoecon Outcomes Res. 2018;10:865\u201371. https:\/\/doi.org\/10.2147\/CEOR.S180491.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"3348_CR59","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.3382","volume":"77","author":"A Zovi","year":"2024","unstructured":"Zovi A, Langella R, Aloisi AC, De Giorgio C, Del Vecchio M, Dondi C, et al. Real-world effectiveness of calcitonin gene-related peptide-binding monoclonal antibodies for migraine prevention: a systematic review. Can J Hosp Pharm. 2024;77(1): e3382. https:\/\/doi.org\/10.4212\/cjhp.3382.","journal-title":"Can J Hosp Pharm"},{"issue":"1","key":"3348_CR60","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s10194-022-01411-1","volume":"23","author":"MT Driessen","year":"2022","unstructured":"Driessen MT, Cohen JM, Patterson-Lomba O, Thompson SF, Seminerio M, Carr K, et al. Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study. J Headache Pain. 2022;23(1):47. https:\/\/doi.org\/10.1186\/s10194-022-01411-1.","journal-title":"J Headache Pain"},{"issue":"11","key":"3348_CR61","doi-asserted-by":"publisher","first-page":"333102423121498","DOI":"10.1177\/03331024231214987","volume":"43","author":"M Ashina","year":"2023","unstructured":"Ashina M, Mitsikostas DD, Amin FM, Kokturk P, Schankin CJ, Sahin G, et al. Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study. Cephalalgia. 2023;43(11):3331024231214987. https:\/\/doi.org\/10.1177\/03331024231214987.","journal-title":"Cephalalgia"},{"issue":"4","key":"3348_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/03331024251321500","volume":"45","author":"R Ornello","year":"2025","unstructured":"Ornello R, Caponnetto V, Ahmed F, Al-Khazali HM, Ambrosini A, Ashina S, et al. Evidence-based guidelines for the pharmacological treatment of migraine, summary version. Cephalalgia. 2025;45(4):1\u201312. https:\/\/doi.org\/10.1177\/03331024251321500.","journal-title":"Cephalalgia"},{"issue":"9","key":"3348_CR63","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1111\/head.14208","volume":"61","author":"DW Dodick","year":"2021","unstructured":"Dodick DW, Tepper SJ, Ailani J, Pannacciulli N, Navetta MS, Loop B, et al. Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data. Headache. 2021;61(9):1411\u201320. https:\/\/doi.org\/10.1111\/head.14208.","journal-title":"Headache"},{"issue":"14","key":"3348_CR64","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1177\/0333102419888222","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ, et al. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia. 2019;39(14):1798\u2013808. https:\/\/doi.org\/10.1177\/0333102419888222.","journal-title":"Cephalalgia"},{"issue":"1","key":"3348_CR65","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s10194-025-02040-0","volume":"26","author":"M Straburzynski","year":"2025","unstructured":"Straburzynski M, Kopyt D, Marschollek K, Blaszczyk B, Kuca-Warnawin E, Kurowska W, et al. Increased infection risk in patients on preventive CGRP-targeting therapies- a meta-analysis and clinical effect assessment. J Headache Pain. 2025;26(1):88. https:\/\/doi.org\/10.1186\/s10194-025-02040-0.","journal-title":"J Headache Pain"},{"issue":"1","key":"3348_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000616","volume":"6","author":"S Naghdi","year":"2024","unstructured":"Naghdi S, Underwood M, Brown A, Matharu M, Duncan C, Davies N, et al. Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review. BMJ Neurol Open. 2024;6(1): e000616. https:\/\/doi.org\/10.1136\/bmjno-2023-000616.","journal-title":"BMJ Neurol Open"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03348-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03348-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03348-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:24:37Z","timestamp":1762262677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03348-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":66,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3348"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03348-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dimos D. Mitsikostas has received consulting fees from AstraZeneca, Bristol Mayers Squibb, Eli Lilly, Lundbeck, Novartis, Pfizer, Roche, and Teva; payment or honoraria for presentations from Allergan\/AbbVie, AstraZeneca, Bristol Mayers Squibb, Eli Lilly, Genesis Pharma, Lundbeck, Merck, Novartis, Roche, and Teva; support for attending meetings or travel from Allergan\/AbbVie, Eli Lilly, Genesis Pharma, Lundbeck, Novartis, and Teva; has performed clinical trials as Principal Investigator for Amgen, Eli Lily, Lundbeck, Novartis, and Pfizer; is the member of the Management Group of Headache Scientific Panel and of Coordinating Panel for Functional Disorder at European Academy of Neurology; and is the president of Hellenic Headache Society. Susanne F. Awad, Rikke Kongerslev, Line Pickering Boserup, and Ravinder Phul are full-time employees of H. Lundbeck A\/S or one of its subsidiary companies. Xin Ying Lee was a full-time employee of H. Lundbeck A\/S during data analysis and initial manuscript stages. She is currently an employee of Novo Nordisk, which was not involved in nor has competing interest with this study. Simona Sacco has received grants or contracts from Novartis and Uriach; has received consulting fees and payment or honoraria for presentations from Abbot, Allergan\/AbbVie, AstraZeneca, Eli Lilly, Lundbeck, Novartis, Novo Nordisk, and Pfizer; support for attending meetings or travel from Eli Lilly, Lundbeck, Novartis, and Teva; equipment or services from Allergan\/AbbVie and Novo Nordisk; is the second vice-president for European Headache Federation; and is the president-elect for European Stroke Organization.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. As such, no direct ethical approval or informed consent was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}